This company has been marked as potentially delisted and may not be actively trading. NASDAQ:MURA Mural Oncology (MURA) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsEarningsFDA EventsInsider TradesNews and TrendsOwnership About Mural Oncology Stock (NASDAQ:MURA) Get Mural Oncology alerts:Sign Up Key Stats Today's Range$2.04▼$2.0450-Day Range$2.02▼$2.1052-Week Range$1.53▼$2.98VolumeN/AAverage Volume227,153 shsMarket Capitalization$35.38 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingSell Company Overview Mural Oncology, Inc. (NASDAQ: MURA) is a clinical-stage biotechnology company focused on discovering and developing innovative therapies for cancer. The company’s research emphasizes targeting the tumor microenvironment and stromal resistance mechanisms to enhance the efficacy of existing and novel oncology agents. Mural’s pipeline features small-molecule programs designed to inhibit signaling pathways involved in tumor growth and extracellular matrix remodeling. Its lead candidates are advancing through early-phase clinical trials in various solid tumors, leveraging translational biology tools such as patient-derived models and molecular profiling to guide drug discovery and patient selection. Headquartered in San Mateo, California, Mural Oncology conducts research and development in the United States and collaborates with academic institutions and industry partners to support global clinical development. The company’s interdisciplinary team combines expertise in oncology research, drug development and translational science to address unmet needs across multiple cancer indications.AI Generated. May Contain Errors. Read More Mural Oncology Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks2nd Percentile Overall ScoreMURA MarketRank™: Mural Oncology scored higher than 2% of companies evaluated by MarketBeat, and ranked 900th out of 905 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion0.5 / 5Analyst RatingSell Consensus RatingMural Oncology has received a consensus rating of Sell. The company's average rating score is 1.00, and is based on no strong buy ratings, no buy ratings, no hold ratings, and 1 sell rating.Amount of Analyst CoverageMural Oncology has received no research coverage in the past 90 days.Read more about Mural Oncology's stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Mural Oncology are expected to grow in the coming year, from ($7.54) to ($4.72) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Mural Oncology is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Mural Oncology is -0.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMural Oncology has a P/B Ratio of 0.25. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for MURA. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMural Oncology does not currently pay a dividend.Dividend GrowthMural Oncology does not have a long track record of dividend growth. News and Social Media0.0 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for Mural Oncology this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Mural Oncology insiders have not sold or bought any company stock.Percentage Held by Insiders2.20% of the stock of Mural Oncology is held by insiders.Percentage Held by Institutions80.21% of the stock of Mural Oncology is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Mural Oncology's insider trading history. Receive MURA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Mural Oncology and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. MURA Stock News HeadlinesFormer Mural Oncology CEO launches new cancer biotech with $225M in venture capitalSeptember 9 at 9:19 AM | bizjournals.comRecursion names Vicki Goodman as CMOMarch 25, 2026 | msn.comYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time through a temporary download link. He plans to charge for it soon. Download your copy now and lock it in at no cost, regardless of future pricing.September 11 at 1:00 AM | Profits Run (Ad)Mural Oncology plc: Mural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | finanznachrichten.deMural Oncology Announces Effectiveness of Scheme of Arrangement and Completion of AcquisitionDecember 5, 2025 | globenewswire.comMural Oncology Announces Sanction of the Scheme by the High CourtDecember 3, 2025 | globenewswire.comMural Oncology plc: Mural Oncology Announces Final Cash Consideration Payable on Closing of Acquisition by XOMA RoyaltyNovember 26, 2025 | finanznachrichten.deMural Oncology announces final cash consideration payable on acquisition closeNovember 26, 2025 | msn.comSee More Headlines MURA Stock Analysis - Frequently Asked Questions How were Mural Oncology's earnings last quarter? Mural Oncology PLC (NASDAQ:MURA) posted its quarterly earnings results on Thursday, November, 6th. The company reported ($0.21) EPS for the quarter, topping the consensus estimate of ($0.59) by $0.38. What other stocks do shareholders of Mural Oncology own? Based on aggregate information from My MarketBeat watchlists, some other companies that Mural Oncology investors own include Meta Platforms (META), NVIDIA (NVDA), Broadcom (AVGO), Arista Networks (ANET), e.l.f. Beauty (ELF), GE Aerospace (GE) and Adobe (ADBE). Company Calendar Last Earnings11/06/2025Today9/11/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (9m+) 1-Year History Sep 25 Dec 25 Mar 26 Jun 26 Sep 26 MURA's financial health is in the Yellow zone, according to TradeSmith. MURA has been in this zone for over 9 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:MURA Previous SymbolNASDAQ:MURA CIK1971543 Webwww.muraloncology.com Phone353-1-905-8020FaxN/AEmployees119Year FoundedN/AProfitability EPS (Trailing Twelve Months)($6.93) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$128.51 million Net MarginsN/A Pretax MarginN/A Return on Equity-112.17% Return on Assets-89.37% Debt Debt-to-Equity RatioN/A Current Ratio5.90 Quick Ratio5.90 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$8.22 per share Price / Book0.25Miscellaneous Outstanding Shares17,344,000Free Float16,962,000Market Cap$35.38 million OptionableOptionable Beta2.93 10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free Report This page (NASDAQ:MURA) was last updated on 9/11/2026 by MarketBeat.com Staff. From Our PartnersALERT: Drop these 5 stocks before the market opens tomorrow!The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...Weiss Ratings | SponsoredThe $15 Gold Fund That Pays Up to $1,152/MonthGold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...Investors Alley | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredLouis Navellier: My #1 AI stock for 2026 (name & ticker inside)Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...InvestorPlace | SponsoredReady to give options a try? Your first trade (Ticker included) -INSIDETired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...Base Camp Trading | SponsoredIran War Shock: What I Was Told In That Private MeetingYou’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...Banyan Hill Publishing | SponsoredHere’s the stock symbol I’ve promisedWhitney Tilson of Stansberry Research has long recommended Berkshire Hathaway as a core retirement holding - b...Stansberry Research | SponsoredMy top 3 AI picks for the next decadeAlexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Mural Oncology PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Mural Oncology With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
